The risk of IFI has been increasing over the last decades mostly because the medical treatments used in specific setting of patients are correlated with severe and prolonged immunosuppression.
However, due to the methodological flaws and the incomplete data in the RENAAL study [ 1], the question of the effectiveness and safety of this drug in the specific setting of patients with diabetic nephropathy remains yet unanswered.
Finally, we will briefly describe some of the toxicities and clinical efficacy of CAR-T cells in the setting of patients with advanced malignancy.
Baseline VOIs and transformed and interpolated follow-up data and a voxel-by-voxel longitudinal mapping of 18 F-FDG uptake in a clinical setting of patients with advanced NSCLC were used.
Our study has clearly demonstrated the benefits, safety, and good tolerability of Kuzik in the prophylaxis of migraine without aura and the use of this medication should be taken in consideration as a good practice in this setting of patients.
In this particular setting of patients, the combined use of various treatment approaches might be beneficial.
However, planning a randomized controlled trial in this setting of patients is hard to hypothesize.
The role of the targeted therapy in these setting of patients has also been evaluated.
Based on these results, authors concluded that MC is a valid option treatment in this setting of patients.
Our study demonstrated that urinary angiotensinogen levels were significantly increased in the setting of patients before the onset of microalbuminuria.
Patients with rapidly progressing disease are an unfavorable setting of patients unlikely to benefit from first-line chemotherapy.
